Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 158

1.

A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3.

Sarathy VV, Pitcher TJ, Gromowski GD, Roehrig JT, Barrett ADT.

J Gen Virol. 2017 Jun;98(6):1299-1304. doi: 10.1099/jgv.0.000785. Epub 2017 Jun 20.

PMID:
28631593
2.

A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Calvert AE, Dixon KL, Piper J, Bennett SL, Thibodeaux BA, Barrett AD, Roehrig JT, Blair CD.

Antiviral Res. 2016 Jul;131:92-9. doi: 10.1016/j.antiviral.2016.04.013. Epub 2016 Apr 26.

3.

Next generation dengue vaccines: A review of the preclinical development pipeline.

Vannice KS, Roehrig JT, Hombach J.

Vaccine. 2015 Dec 10;33(50):7091-9. doi: 10.1016/j.vaccine.2015.09.053. Epub 2015 Sep 28. Review.

4.

Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies.

Porta J, Jose J, Roehrig JT, Blair CD, Kuhn RJ, Rossmann MG.

J Virol. 2014 Sep 1;88(17):9616-23. doi: 10.1128/JVI.01286-14. Epub 2014 Jun 11.

5.

Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection.

Chotiwan N, Roehrig JT, Schlesinger JJ, Blair CD, Huang CY.

Virology. 2014 May;456-457:238-46. doi: 10.1016/j.virol.2014.03.031. Epub 2014 Apr 18.

6.

Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.

Julander JG, Thibodeaux BA, Morrey JD, Roehrig JT, Blair CD.

Antiviral Res. 2014 Mar;103:32-8. doi: 10.1016/j.antiviral.2013.12.011. Epub 2014 Jan 3.

7.

West nile virus in the United States - a historical perspective.

Roehrig JT.

Viruses. 2013 Dec 10;5(12):3088-108. doi: 10.3390/v5123088. Review.

8.

Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain.

Calvert AE, Dixon KL, Delorey MJ, Blair CD, Roehrig JT.

Vaccine. 2014 Jan 3;32(2):258-64. doi: 10.1016/j.vaccine.2013.11.016. Epub 2013 Nov 17.

9.

BodiMojo: effective Internet-based promotion of positive body image in adolescent girls.

Franko DL, Cousineau TM, Rodgers RF, Roehrig JP.

Body Image. 2013 Sep;10(4):481-8. doi: 10.1016/j.bodyim.2013.04.008. Epub 2013 Jun 13.

10.

Race/ethnicity, education, and treatment parameters as moderators and predictors of outcome in binge eating disorder.

Thompson-Brenner H, Franko DL, Thompson DR, Grilo CM, Boisseau CL, Roehrig JP, Richards LK, Bryson SW, Bulik CM, Crow SJ, Devlin MJ, Gorin AA, Kristeller JL, Masheb R, Mitchell JE, Peterson CB, Safer DL, Striegel RH, Wilfley DE, Wilson GT.

J Consult Clin Psychol. 2013 Aug;81(4):710-21. doi: 10.1037/a0032946. Epub 2013 May 6.

11.

Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion.

Roehrig JT, Butrapet S, Liss NM, Bennett SL, Luy BE, Childers T, Boroughs KL, Stovall JL, Calvert AE, Blair CD, Huang CY.

Virology. 2013 Jul 5;441(2):114-25. doi: 10.1016/j.virol.2013.03.011. Epub 2013 Apr 6.

12.

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation.

Live Dengue Vaccines Technical Consultation Reporting Group, Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, Hombach J, Farrar J.

Vaccine. 2013 May 28;31(23):2603-9. doi: 10.1016/j.vaccine.2013.03.038. Epub 2013 Apr 6.

13.

Application of the radiating effect concept to implement measures stipulated by the European Water Framework Directive.

Meier G, Zumbroich T, Roehrig J, Souvignet M.

Water Sci Technol. 2012;66(12):2793-9. doi: 10.2166/wst.2012.532.

PMID:
23109600
14.

Characteristics of predrinking and associated risks: a survey in a sample of German high school students.

Wahl S, Sonntag T, Roehrig J, Kriston L, Berner MM.

Int J Public Health. 2013 Apr;58(2):197-205. doi: 10.1007/s00038-012-0409-2. Epub 2012 Sep 25.

PMID:
23007874
15.

Social-cognitive correlates of fruit and vegetable consumption in minority and non-minority youth.

Franko DL, Cousineau TM, Rodgers RF, Roehrig JP, Hoffman JA.

J Nutr Educ Behav. 2013 Mar;45(2):96-101. doi: 10.1016/j.jneb.2011.11.006. Epub 2012 Aug 26.

16.

Mutations in the West Nile prM protein affect VLP and virion secretion in vitro.

Calvert AE, Huang CY, Blair CD, Roehrig JT.

Virology. 2012 Nov 10;433(1):35-44. doi: 10.1016/j.virol.2012.07.011. Epub 2012 Jul 31.

17.

State health department perceived utility of and satisfaction with ArboNET, the U.S. National Arboviral Surveillance System.

Lindsey NP, Brown JA, Kightlinger L, Rosenberg L, Fischer M; ArboNET Evaluation Working Group.

Public Health Rep. 2012 Jul-Aug;127(4):383-90.

18.

Considering J.Lo and Ugly Betty: a qualitative examination of risk factors and prevention targets for body dissatisfaction, eating disorders, and obesity in young Latina women.

Franko DL, Coen EJ, Roehrig JP, Rodgers RF, Jenkins A, Lovering ME, Dela Cruz S.

Body Image. 2012 Jun;9(3):381-7. doi: 10.1016/j.bodyim.2012.04.003. Epub 2012 May 18.

PMID:
22609033
19.

A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.

Thibodeaux BA, Garbino NC, Liss NM, Piper J, Blair CD, Roehrig JT.

Vaccine. 2012 May 2;30(21):3180-7. doi: 10.1016/j.vaccine.2012.03.003. Epub 2012 Mar 13.

20.

A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Thibodeaux BA, Garbino NC, Liss NM, Piper J, Schlesinger JJ, Blair CD, Roehrig JT.

Antiviral Res. 2012 Apr;94(1):1-8. doi: 10.1016/j.antiviral.2012.02.001. Epub 2012 Feb 15.

Supplemental Content

Loading ...
Support Center